X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

International collaboration finds 11 new Alzheimer’s genes to target for drug discovery

Yuvraj_pawp by Yuvraj_pawp
28th October 2013
in Americas, News

University of Miami Miller School of Medicine researchers played a key role in the largest international Alzheimer’s disease genetics collaboration to date, which identified 11 new regions of the genome that contribute to late-onset Alzheimer’s disease, doubling the number of potential genetics-based therapeutic targets to investigate.

Published October 27 in Nature Genetics, the study gives a broader view of the genetic factors contributing to Alzheimer’s and expands the understanding of the disease to new areas, including the immune system, where a genetic overlap with other neurodegenerative diseases, including multiple sclerosis and Parkinson’s disease, was identified.

In 2011, the world’s four largest research consortia on the genetics of Alzheimer’s disease joined efforts to discover and map the genes that contribute to Alzheimer’s, forming the International Genomics of Alzheimer’s Project (IGAP). The team collected genetic information from 25,500 Alzheimer’s disease patients and 49,038 controls from 15 countries to perform this two-stage meta-analysis that resulted in the discovery of 11 new genes in addition to those already known, and the identification of 13 other genes, yet to be validated.

Margaret A. Pericak-Vance, Ph.D., the Dr. John T. Macdonald Foundation Professor of Human Genomics and Director of the John P. Hussman Institute for Human Genomics at the Miller School, and Lindsay A. Farrer, Ph.D., from Boston University, led the analysis teams for the American Alzheimer’s Disease Genetics Consortium, which includes nearly all of the nation’s researchers working on the genetics of Alzheimer’s, as well as many investigators and resources of the 29 federally funded Alzheimer’s Disease Centers.

Several of the genes the researchers identified confirmed known biological pathways of Alzheimer’s disease, including the role of the amyloid (SORL1, CASS4) and tau (CASS4, FERMT2) pathways. Newly discovered genes involved in the immune response and inflammation (HLA-DRB5/DRB1, INPP5D, MEF2C) reinforced a pathway implied by previous work (on CR1, TREM2). Additional genes related to cell migration (PTK2B), lipid transport and endocytosis (SORL1) also were confirmed, and new hypotheses emerged related to hippocampal synaptic function (MEF2C, PTK2B), the cytoskeleton and axonal transport (CELF1, NME8, CASS4), as well as myeloid and microglial cell functions (INPP5D).

One of the more significant new associations was found in the HLA-DRB5/DRB1 region, one of the most complex parts of the genome, which plays a role in the immune system and inflammatory response. It also has been associated with multiple sclerosis and Parkinson’s disease, suggesting that the diseases where abnormal proteins accumulate in the brain may have a common mechanism involved, and possibly a common drug target.

“The discovery of novel pathways is very encouraging considering the limited success of Alzheimer’s disease drugs tested so far,” Pericak-Vance said. “Our findings bring us closer toward identifying new drug targets for Alzheimer’s and other neurodegenerative diseases. We’ll continue to expand and analyze our data set with this incredible group so that we can better understand the genetic influences on this devastating disease, and find new medical and therapeutic interventions.”

Tags: America
Previous Post

AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability

Next Post

Stem cell breakthrough could set up future transplant therapies

Related Posts

Lonza To Construct $518mn Fill-Finish Plant In Switzerland
Manufacturing

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

8th July 2022
Pfizer And Touchlight Enter Into A Patent Collaboration
Manufacturing

Pfizer And Touchlight Enter Into A Patent Collaboration

8th July 2022
AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged
Manufacturing

AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

8th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Manufacturing

Paxlovid Allowed By FDA To Sell At Certified Pharmacies

8th July 2022
Deloitte Believes Mature R&D Firms Reap Enterprise Value
Manufacturing

Deloitte Believes Mature R&D Firms Reap Enterprise Value

7th July 2022
Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
Next Post

Stem cell breakthrough could set up future transplant therapies

Latest News

Lonza To Construct $518mn Fill-Finish Plant In Switzerland
Manufacturing

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

8th July 2022
Pfizer And Touchlight Enter Into A Patent Collaboration
Manufacturing

Pfizer And Touchlight Enter Into A Patent Collaboration

8th July 2022
AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged
Manufacturing

AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

8th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Manufacturing

Paxlovid Allowed By FDA To Sell At Certified Pharmacies

8th July 2022
Deloitte Believes Mature R&D Firms Reap Enterprise Value
Manufacturing

Deloitte Believes Mature R&D Firms Reap Enterprise Value

7th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In